Sentinel Lymph Node Clinical Trial
Official title:
Study to Evaluate the Efficacy of Early Detection of Lower Extremity Lymphedema After Lymphadenectomy in Gynecological Cancer and Implantation of the Protocol
This study aims to detect and treat early lower limb lymphedema secondary to lymphadenectomy
with the aim of increasing the quality of life of patients with this chronic condition.
To this end, a group of patients (treatment group) will be referred to the Rehabilitation
service for a previous consultation and after surgery where lymphedema could be detected
early. In addition, the usual follow-up will be carried out in Gynecology Oncology
consultation (GO). In the second group, also called control, will be performed the usual
follow-up in GO.
For this we randomize to one of these two groups. The research project has the favorable
report of the Center's Clinical Research Ethics Committee
METHODOLOGY:
1. Type of study: A) Randomized clinical trial B) Prospective cohort observational study
2. Study period: from January 2017 to December 2017.
3. Scope: health area of the province of Gipuzkoa and the University Hospital of Donostia
as a reference center.
4. Selection of the population:
4.1. The inclusion criteria will be: A) Diagnostic gynecological cancer patients
submitted to bilateral laparoscopic pelvic lymphadenectomy as laparotomics (B: Sentinel
Node Biopsy study, SNB) within the usual surgical protocol, with expected survival
greater than 12 weeks and adequate liver, renal and medullary functions to accept And
sign informed consent 4.2. The exclusion criteria for the study will be: Blood clotting
or hematological disorders, previous thromboembolic disease and history of lymphatic
system disease (lymphedema or lymphocele), contraindication for physiotherapy or who do
not wish to participate and / or do not sign informed consent.
4.3. Sample size: A) Assuming that according to previous studies the overall incidence
of lymphedema after LPL is 21% (Hareyama et al), its estimated that a minimum sample of
44 patients will bi needed in order to be able to demonstrate at least 4-fold detection
(Torres et al) of Lymphedemas with early follow-up with alpha = 0.05 and beta = 0.2,
estimating that habitual follow-up detects 13% of lymphedema ( Mohler III et al).
4.4. Recruitment Process: Will be selected consecutively and offered to participate in
the study.
5. 5.1 Intervention: A) After diagnosis and programming for surgery at the GO consultation,
circometry is performed by a trained nurse. During the admission, the nurse delivers and
explains recommendations sheet and is offered to participate in the clinical trial
giving him the Informed Consent (IC) and Information Sheet created for this purpose. In
case of accepting and signing the IC, it is randomized (total randomization) according
to system of envelopes with code.
Distribution of the intervention;
- Treatment group: Face-to-face consultation in Rehabilitation for early detection of
lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
- Control group: The usual follow-up will be carried out in GO consultation (0,1,6,12
months)
The pelvic lymphadenectomy will be performed by the same surgical team using a
transperitoneal approach. The limits of lymph node dissection will be: the psoas muscle,
laterally, the postero-medially internal iliac artery, the bifurcation of the common iliac
artery cranially, where it crosses the ureter, and caudally the origin of the epigastric
vessels, to level of the deep circumflex iliac vein.
B) After diagnosis and programming for surgery at the GO consultation, circometry is
performed by trained and yearly nurse. During the entrance, it is delivered and explains the
recommendations sheet. SNB is performed by detecting sentinel ganglion from the above
mentioned areas according to the protocol of the service. The usual follow-up will be carried
out in GO consultation (0,1,6,12 months)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05437380 -
Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC
|
N/A | |
Active, not recruiting |
NCT04303715 -
No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography
|
N/A | |
Completed |
NCT05498051 -
Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.
|
N/A | |
Active, not recruiting |
NCT06169787 -
Sentinel Lymph Nodes Biopsy in Cervical Cancer
|
||
Completed |
NCT03294330 -
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04930692 -
A Prospective Single-center Cohort Study "Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients"
|
N/A | |
Recruiting |
NCT03749707 -
HPV in Sentinel Lymph Nodes
|
N/A | |
Completed |
NCT03899441 -
Multimedia Aid Gynecologic Counseling and Consent
|
N/A | |
Recruiting |
NCT04826211 -
Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI
|
N/A | |
Not yet recruiting |
NCT06130241 -
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Initially Node Positive Breast Cancer Patients, Could it Omit Axillary Dissection ?
|
N/A | |
Recruiting |
NCT04664582 -
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
|
N/A | |
Withdrawn |
NCT04487912 -
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
|
Phase 4 | |
Completed |
NCT03563781 -
SEntine Lymph Node in earLY Ovarian Cancer (SELLY)
|
N/A | |
Recruiting |
NCT05623280 -
Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.
|
||
Active, not recruiting |
NCT05359783 -
Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04568941 -
Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer
|
N/A | |
Completed |
NCT03606616 -
Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients
|
||
Recruiting |
NCT02982148 -
Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients
|
Phase 4 | |
Recruiting |
NCT06161428 -
Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer
|
||
Completed |
NCT03900104 -
Cervical and Endometrial Injection for Sentinel Lymph Node Detection in Endometrial Cancer
|
N/A |